NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

先天性纖毛運動異常症(PCD)- 市場洞察,流行病學,市場預測 2028年

Primary Ciliary Dyskinesia - Market Insights, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 911511
出版日期 按訂單生產 內容資訊 英文 213 Pages
商品交期: 2-10個工作天內
價格
先天性纖毛運動異常症(PCD)- 市場洞察,流行病學,市場預測 2028年 Primary Ciliary Dyskinesia - Market Insights, Epidemiology and Market Forecast - 2028
出版日期: 按訂單生產內容資訊: 英文 213 Pages
簡介

主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的先天性纖毛運動異常症(PCD)的2017年的患病數估計為8萬815人,以及市場規模為4億9,066萬美元。

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的先天性纖毛運動異常症(PCD)市場調查,市場概要,疾病及新藥概要,整體及各國的市場趨勢,病例,研究促進計劃,流行病學的預測,市場規模,患病數的變化與預測,未滿足需求,市場成長要素及障礙等資料彙整。

目錄

第1章 重要洞察

第2章 先天性纖毛運動異常症(PCD)的流行病學

第3章 先天性纖毛運動異常症(PCD)的市場概要

  • 分佈情形(成果值)
  • 分佈情形(預測值)

第4章 疾病背景和概要

  • 簡介
  • 原因
  • 危險因素
  • 徵兆與症狀

第5章 遺傳模式

  • 症狀
  • 遺傳學
  • 病理生理學
  • 相關疾病
  • 診斷方法
    • 診斷檢驗
    • 推薦診斷標準:各年齡
    • 非推薦檢驗
  • 歐洲呼吸系統學會(ERS)的先天性纖毛運動異常症(PCD)診斷的指南
  • 北美PCD財團的指南
  • 歐洲呼吸系統學會(ERS)和北美PCD財團的指南比較
  • 美國胸部學會(ATS)的先天性纖毛運動異常症(PCD)診斷的指南
  • 先天性纖毛運動異常症(PCD)診斷的未來展望

第6章 治療

  • 治療流程
  • 治療:各病例

第7章 未滿足需求

第8章 PCD的治療貢獻的組織

第9章 關鍵意見領袖的意見

第10章 關鍵交叉競爭者

第11章 新藥

  • VX-371:Vertex Pharmaceuticals
    • 產品概要
    • 其他開發趨勢
    • 臨床開發
    • 產品簡介
  • POL6014:Santhera Pharmaceuticals
  • Primary Ciliary Dyskinesia Research Program:Translate Bio
  • SNSP113:Synspira Therapeutics
  • ELX-02:Eloxx Pharmaceuticals

第12章 流行病學和患者人口

  • 主要調查結果

第13章 主要7個國家的先天性纖毛運動異常症(PCD)的患病數

第14章 先天性纖毛運動異常症(PCD)的流行病學:各國

  • 美國
    • 假設和根據
    • 總患病數
    • 總診斷數
    • 臨床症狀
  • 歐洲5個國家
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第15章 病例報告

第16章 先天性纖毛運動異常症(PCD)研究的促進計劃

  • BESTCILIA
  • BEAT-PCD

第17章 主要7個國家的先天性纖毛運動異常症(PCD)市場分析

  • 主要調查結果
  • 主要7個國家的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物

第18章 美國市場預測

  • 美國的市場規模
  • 整體市場規模
  • 市場規模:各治療藥物

第19章 市場預測歐洲5個國家

  • 德國的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物
  • 法國的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物
  • 義大利的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物
  • 西班牙的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物
  • 英國的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物

第20章 日本市場預測

  • 整體市場規模
  • 市場規模:各治療藥物

第21章 市場成長要素

第22章 市場障礙

第23章 附錄

  • 調查手法

第24章 DelveInsight的服務內容

第25章 免責聲明

第26章 關於DelveInsight

目錄
Product Code: DIMI0661

DelveInsight's Primary Ciliary Dyskinesia - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Primary Ciliary Dyskinesia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Primary Ciliary Dyskinesia (PCD) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Primary Ciliary Dyskinesia - Disease Understanding and Treatment Algorithm

The DelveInsight Primary Ciliary Dyskinesia (PCD) market report gives the thorough understanding of the Primary Ciliary Dyskinesia (PCD) by including details such as disease definition, causes, symptoms, pathophysiology, and diagnostic trends. It also provides overview of treatment and management of the disease in the US, EU5 and Japan.

Primary ciliary dyskinesia (PCD) is an autosomal recessive genetic disorder caused by the impaired function of cilia of the respiratory tract epithelial cells, which may also involve other ciliated cells in the reproductive system of the male or female.

Primary Ciliary Dyskinesia Epidemiology

The Primary Ciliary Dyskinesia epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and the prevalence based on clinical manifestations in the US, EU5 and Japan.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed prevalent cases, and prevalence based on clinical manifestations) scenario of Primary Ciliary Dyskinesia in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, total prevalent population of Primary Ciliary Dyskinesia in seven major markets was found to be 80,815 in 2017. 

Primary Ciliary Dyskinesia Drug Chapters

This segment of the PCD Drug report encloses the detailed analysis of the emerging drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, and the latest news and press releases.

At present, therapeutic approach of PCD involves symptomatic treatment. The PCD market forecast provided in the report solely focuses on the market revenue generated by the off-label systemic therapies, such as antibiotics, inhaled corticosteroids, rhDNase and bronchodilators. Till date no drug has obtained approval for the treatment of PCD. Detailed chapter for upcoming therapies like Vertex Pharmaceuticals novel inhibitor of the epithelial sodium channel (ENaC) VX-371, and other promising therapies such as POL6014 (Santhera Pharmaceuticals) have been covered in the report.

Primary Ciliary Dyskinesia (PCD) Market Outlook

The PCD market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers.

This segment gives a through detail of emerging therapies and other promising therapies by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Primary Ciliary Dyskinesia (PCD) in 7MM was found to be USD 490.66 million in 2017.

Primary Ciliary Dyskinesia (PCD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs that will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Primary Ciliary Dyskinesia (PCD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Primary Ciliary Dyskinesia (PCD) Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Market Size by Therapies
  • Key Cross Competition

Primary Ciliary Dyskinesia (PCD) Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Primary Ciliary Dyskinesia (PCD) market.
  • Organize sales and marketing efforts by identifying the best opportunities for Primary Ciliary Dyskinesia (PCD) market.
  • To understand the future market competition in the Primary Ciliary Dyskinesia (PCD) market.

Table of Contents

1. Key Insights

2. Primary Ciliary Dyskinesia: Epidemiology Overview at a Glance

3. Primary Ciliary Dyskinesia: Market Overview at a Glance

  • 3.1 Total Market Share (%) Distribution of Primary Ciliary Dyskinesia in 2017
  • 3.2 Total Market Share (%) Distribution of Primary Ciliary Dyskinesia in 2028

4. Primary Ciliary Dyskinesia (PCD): Disease Background and Overview

  • 4.1 Introduction
  • 4.2 Causes
  • 4.3 Risk Factors
  • 4.4 Signs and Symptoms

5. Inheritance pattern

  • 5.1 Disease Manifestations
  • 5.2 Genetics
  • 5.3 Pathophysiology
    • 5.3.1 Structure and function of cilia
    • 5.3.2 Ciliary ultrastructural defects
    • 5.3.3 Proposed Pathogenesis of Primary Ciliary Dyskinesia Lung Disease
  • 5.4 Related Disorders
  • 5.5 Diagnostic Approach
    • 5.5.1 Diagnostic Tests
    • 5.5.2 Recommended PCD Diagnostic Criteria by Age
    • 5.5.3 Tests Not Recommended for PCD Diagnosis
    • 5.5.4 European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia
  • 5.6 North American Primary Ciliary Dyskinesia (PCD) Foundation guidelines
  • 5.7 A comparison between the European Respiratory Society (ERS) and North American primary ciliary dyskinesia (PCD) Foundation guidelines
  • 5.8 American Thoracic Society (ATS) Guideline Aids in Diagnosing Primary Ciliary Dyskinesia
    • 5.8.1 Primary Ciliary Dyskinesia (PCD) Management
    • 5.8.2 Diagnostic algorithm for Primary Ciliary Dyskinesia
  • 5.9 Future Prospects of Primary Ciliary Dyskinesia Diagnosis

6. Treatment

  • 6.1 Treatment Algorithm
  • 6.2 Manifestation-wise Treatment
    • 6.2.1 Respiratory Manifestations Treatment
    • 6.2.2 Ear, nose and throat problems in PCD
    • 6.2.3 Other Systems

7. Unmet Needs

8. Organizations contributing toward PCD

9. KOL's Views: Primary Ciliary Dyskinesia

10. Key Cross Competitors

11. Emerging Therapies

  • 11.1 VX-371: Vertex Pharmaceuticals
    • 11.1.1 Product Description
    • 11.1.2 Other development Activities
    • 11.1.3 Clinical Development
    • 11.1.4 Product Profile
  • 11.2 POL6014: Santhera Pharmaceuticals
    • 11.2.1 Product Description
    • 11.2.2 Other development Activities
    • 11.2.3 Product Profile
  • 11.3 Primary Ciliary Dyskinesia Research Program: Translate Bio
    • 11.3.1 Product Description
    • 11.3.2 Product Profile
  • 11.4 SNSP113: Synspira Therapeutics
    • 11.4.1 Product Description
    • 11.4.2 Other development Activities
    • 11.4.3 Clinical Development
    • 11.4.4 Product Profile
  • 11.5 ELX-02: Eloxx Pharmaceuticals
    • 11.5.1 Product Description
    • 11.5.2 Other development Activities
    • 11.5.3 Product Profile
  • 11.6 Future Treatment Therapies for Primary Ciliary Dyskinesia

12. Epidemiology and Patient Population

  • 12.1 Key Findings

13. 7MM Total Prevalent Patient Population of PCD

14. Country Wise-Epidemiology of Primary Ciliary Dyskinesia

  • 14.1 United States
    • 14.1.1 Assumptions and Rationale
    • 14.1.2 Total Prevalent Population of Primary Ciliary Dyskinesia
    • 14.1.3 Total Diagnosed Population of Primary Ciliary Dyskinesia
    • 14.1.4 Clinical Manifestations of Primary Ciliary Dyskinesia
  • 14.2 EU5 Countries
    • 14.2.1 Assumptions and Rationale
  • 14.3 Germany
    • 14.3.1 Total Prevalent Population of Primary Ciliary Dyskinesia
    • 14.3.2 Total Diagnosed Population of Primary Ciliary Dyskinesia
    • 14.3.3 Clinical Manifestations of Primary Ciliary Dyskinesia
  • 14.4 France
    • 14.4.1 Total Prevalent Population of Primary Ciliary Dyskinesia
    • 14.4.2 Total Diagnosed Population of Primary Ciliary Dyskinesia
    • 14.4.3 Clinical Manifestations of Primary Ciliary Dyskinesia
  • 14.5 Italy
    • 14.5.1 Total Prevalent Population of Primary Ciliary Dyskinesia
    • 14.5.2 Total Diagnosed Population of Primary Ciliary Dyskinesia
    • 14.5.3 Clinical Manifestations of Primary Ciliary Dyskinesia
  • 14.6 Spain
    • 14.6.1 Total Prevalent Population of Primary Ciliary Dyskinesia
    • 14.6.2 Total Diagnosed Population of Primary Ciliary Dyskinesia
    • 14.6.3 Clinical Manifestations of Primary Ciliary Dyskinesia
  • 14.7 United Kingdom
    • 14.7.1 Total Prevalent Population of Primary Ciliary Dyskinesia
    • 14.7.2 Total Diagnosed Population of Primary Ciliary Dyskinesia
    • 14.7.3 Clinical Manifestations of Primary Ciliary Dyskinesia
  • 14.8 Japan
    • 14.8.1 Assumptions and Rationale
    • 14.8.2 Total Prevalent Population of Primary Ciliary Dyskinesia
    • 14.8.3 Total Diagnosed Population of Primary Ciliary Dyskinesia
    • 14.8.4 Clinical Manifestations of Primary Ciliary Dyskinesia

15. Case-Reports

  • 15.1 Diagnostic Journey of a girl who couldn't stop coughing
  • 15.2 Early Lung Disease in Young Children with Primary Ciliary Dyskinesia - Therapeutic Perspective
  • 15.3 Ultrastructural pathology of primary ciliary dyskinesia: report about 125 cases in Germany - Diagnostic Perspective
  • 15.4 Individualized physical training in the therapy of Primary Ciliary Dyskinesia - A case report - Preventive Therapy Perspective
  • 15.5 Kartagener's syndrome
  • 15.6 Nasal nitric oxide is low early in life: case study of two infants with primary ciliary dyskinesia

16. Projects aimed to push the research of Primary Ciliary Dyskinesia forward

  • 16.1 BESTCILIA Project (Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia) - December 2012 - May 2016 (Duration 42 months)
    • 16.1.1 Executive Summary
    • 16.1.2 Project Context and Objectives
    • 16.1.3 Project Results
    • 16.1.4 Potential Impact
    • 16.1.5 Dissemination of project results - discourse with the scientific community
    • 16.1.6 Funding
  • 16.2 BEAT - PCD (Better Experimental Approaches to Treat Primary Ciliary Dyskinesia)
    • 16.2.1 Introduction
    • 16.2.2 Objectives
    • 16.2.3 Proceedings of the COST action BM1407 inaugural conference BEAT-PCD: translational research in primary ciliary dyskinesia - bench, bedside, and population perspectives - Summary

17. Primary Ciliary Dyskinesia: 7 Major Market Analysis

  • 17.1 Key Findings
  • 17.2 Market Size of Primary Ciliary Dyskinesia in 7MM
    • 17.2.1 Total Market Size of Primary Ciliary Dyskinesia
    • 17.2.2 Market Size of Primary Ciliary Dyskinesia by Therapies

18. United States Market Outlook

    • 18.1.1 United States Market Size
    • 18.1.2 Total Market Size of Primary Ciliary Dyskinesia
    • 18.1.3 Market Size of Primary Ciliary Dyskinesia by Therapies

19. EU-5 Countries: Market Outlook

  • 19.1 Germany
    • 19.1.1 Total Market size of Primary Ciliary Dyskinesia
    • 19.1.2 Market Size of Primary Ciliary Dyskinesia by Therapies
  • 19.2 France
    • 19.2.1 Total Market Size of Primary Ciliary Dyskinesia
    • 19.2.2 Market Size of Primary Ciliary Dyskinesia by Therapies
  • 19.3 Italy
    • 19.3.1 Total Market Size of Primary Ciliary Dyskinesia
    • 19.3.2 Market Size of Primary Ciliary Dyskinesia by Therapies
  • 19.4 Spain
    • 19.4.1 Total Market Size of Primary Ciliary Dyskinesia
    • 19.4.2 Market Size of Primary Ciliary Dyskinesia by Therapies
  • 19.5 United Kingdom
    • 19.5.1 Total Market Size of Primary Ciliary Dyskinesia
    • 19.5.2 Market Size of Primary Ciliary Dyskinesia by Therapies

20. Japan: Market Outlook

  • 20.1 Total Market Size of Primary Ciliary Dyskinesia
  • 20.2 Market Size of Primary Ciliary Dyskinesia by Therapies

21. Market Drivers

22. Market Barriers

23. Appendix

  • 23.1 Report Methodology

24. DelveInsight Capabilities

25. Disclaimer

26. About DelveInsight

List of Tables

Table 1 Genes associated with Primary Ciliary Dyskinesia and corresponding ultrastructure

Table 2 Recommended Diagnostic Testing Methods for Primary Ciliary Dyskinesia

Table 3 Tests NOT Recommended for Diagnosing Primary Ciliary Dyskinesia

Table 4 Other Chronic Respiratory Conditions to Consider When Considering a Diagnosis of PCD

Table 5 Other Diseases Co-Segregating With PCD

Table 6 Recommended Diagnostic Testing Methods for Primary Ciliary Dyskinesia

Table 7 Tests NOT Recommended for Diagnosing Primary Ciliary Dyskinesia

Table 8 Other Chronic Respiratory Conditions to Consider When Considering a Diagnosis of PCD

Table 9 Other Diseases Co-Segregating With PCD

Table 10 Suggested Schedule of Investigations and Clinical Care in Primary Ciliary Dyskinesia

Table 11 Comparison of European Respiratory Society & North American PCD Foundation guidelines

Table 12 Summary table of lower respiratory treatment recommendations in PCD

Table 13 Organizations contributing toward PCD

Table 14 Comparison Of Drugs Under Development For Primary Ciliary Dyskinesia

Table 15 VX-371 Clinical Trial Description, 2019

Table 16 Total Prevalent Population of PCD in the 7MM (2017-2028)

Table 17 Total Prevalent Population of PCD in the US (2017-2028)

Table 18 Diagnosed Cases of PCD in the US (2017-2028)

Table 19 Clinical Mannifestations associated with Primary Ciliary Dyskine in the US (2017-2028)

Table 20 Situs Anomalies associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Table 21 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Table 22 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Table 23 Other Manifestations associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Table 24 Total Prevalent Population of PCD in Germany (2017-2028)

Table 25 Diagnosed Cases of PCD in Germany (2017-2028)

Table 26 Clinical Mannifestations associated with Primary Ciliary Dyskinesia in Germany (2017-2028)

Table 27 Situs Anomalies associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Table 28 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Germany (2017-2028)

Table 29 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Germany (2017-2028)

Table 30 Other Manifestations associated with Primary Ciliary Dyskinesia in Germany (2017-2028)

Table 31 Total Prevalent Population of PCD in France (2017-2028)

Table 32 Diagnosed Cases of PCD in France (2017-2028)

Table 33 Clinical Mannifestations associated with Primary Ciliary Dyskinesia in France (2017-2028)

Table 34 Situs Anomalies associated with Primary Ciliary Dyskinesia in France (2017-2028)

Table 35 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in France (2017-2028)

Table 36 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in France (2017-2028)

Table 37 Other Manifestations associated with Primary Ciliary Dyskinesia in France (2017-2028)

Table 38 Total Prevalent Population of PCD in Italy (2017-2028)

Table 39 Diagnosed Cases of PCD in Italy (2017-2028)

Table 40 Clinical Manifestations associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Table 41 Situs Anomalies associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Table 42 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Table 43 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Table 44 Other Manifestations associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Table 45 Total Prevalent Population of PCD in Spain (2017-2028)

Table 46 Diagnosed Cases of PCD in Spain (2017-2028)

Table 47 Clinical Manifestations associated with Primary Ciliary Dyskinesia in Spain (2017-2028)

Table 48 Situs Anomalies associated with Primary Ciliary Dyskinesia in Spain(2017-2028)

Table 49 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Spain (2017-2028)

Table 50 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Spain (2017-2028)

Table 51 Other Manifestations associated with Primary Ciliary Dyskinesia in Spain (2017-2028)

Table 52 Total Prevalent Population of PCD in United Kingdom (2017-2028)

Table 53 Diagnosed Cases of PCD in United Kingdom (2017-2028)

Table 54 Clinical Mannifestations associated with Primary Ciliary Dyskinesia in the United Kingdom (2017-2028)

Table 55 Situs Anomalies associated with PCD in United Kingdom (2017-2028)

Table 56 Lower Respiratory Tract Anomalies associated with PCD in United Kingdom (2017-2028)

Table 57 Upper Respiratory Tract Anomalies associated with PCD in United Kingdom (2017-2028)

Table 58 Other Manifestations associated with PCD in United Kingdom (2017-2028)

Table 59 Total Prevalent Population of PCD in Japan (2017-2028)

Table 60 Diagnosed Cases of PCD in Japan (2017-2028)

Table 61 Clinical Manifestations associated with Primary Ciliary Dyskinesia in Japan (2017-2028)

Table 62 Situs Anomalies associated with Primary Ciliary Dyskinesia in Japan (2017-2028)

Table 63 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Japan (2017-2028)

Table 64 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Japan (2017-2028)

Table 65 Other Manifestations associated with Primary Ciliary Dyskinesia in Japan (2017-2028)

Table 66 7 Major Market Size of Primary Ciliary Dyskinesia in USD Million ( 2017-2028)

Table 67 7 Major Market Size of Primary Ciliary Dyskinesia by Therapies in USD Million ( 2017-2028)

Table 68 Total Market Size of Primary Ciliary Dyskinesia in the United States (2017-2028)

Table 69 The United States Market Size of Primary Ciliary Dyskinesia by Therapies in USD Million (2017-2028)

Table 70 Total Market Size of Primary Ciliary Dyskinesia in Germany (2017-2028)

Table 71 Germany Market Size of Primary Ciliary Dyskinesia by Therapies in USD Million ( 2017-2028)

Table 72 Total Market Size of Primary Ciliary Dyskinesia in France (2017-2028)

Table 73 France Market Size of Primary Ciliary Dyskinesia by Therapies in USD Million ( 2017-2028)

Table 74 Total Market Size of Primary Ciliary Dyskinesia in Italy (2017-2028)

Table 75 Italy Market Size of Primary Ciliary Dyskinesia by Therapies in USD Million (2017-2028)

Table 76 Total Market Size of Primary Ciliary Dyskinesia in Spain (2017-2028)

Table 77 Spain Market Size of Primary Ciliary Dyskinesia by Therapies in USD Million (2017-2028)

Table 78 Total Market Size of Primary Ciliary Dyskinesia in United Kingdom (2017-2028)

Table 79 United Kingdom Market Size of Primary Ciliary Dyskinesia by Therapies in USD Million (2017-2028)

Table 80 Total Market Size of Primary Ciliary Dyskinesia in Japan (2017-2028)

Table 81 The United States Market Size of Primary Ciliary Dyskinesia by Therapies in USD Million ( 2017-2028)

List of Figures

  • Figure 1: Total Prevalent Population of PCD in the 7 MM (2017)
  • Figure 2: Total Prevalent Population of PCD in the 7 MM (2028)
  • Figure 3: Total Market Share (%) Distribution of Primary Ciliary Dyskinesia in 2017
  • Figure 4: Total Market Share (%) Distribution of Primary Ciliary Dyskinesia in 2028
  • Figure 5: Organs affected by Primary Ciliary Dyskinesia
  • Figure 6: Risk Factors of Primary Ciliary Dyskinesis
  • Figure 7: Symptoms associated with Primary Ciliary Dyskinesia
  • Figure 8: Inheritance Pattern of PCD
  • Figure 9: The classical clinical phenotypes of Primary Ciliary Dyskinesia at various ages
  • Figure 10: The classical clinical phenotypes of Primary Ciliary Dyskinesia at various ages
  • Figure 11: Proposed pathogenesis of primary ciliary dyskinesia lung disease
  • Figure 12: PCD classification according to the European Respiratory Society guidelines for the diagnosis of PCD.
  • Figure 13: Algorithm for diagnostic assessment of patients for PCD proposed by the ERS Task Force
  • Figure 14: Further steps after diagnostic workup and management for patients
  • Figure 15: Diagnostic algorithm for primary ciliary dyskinesia
  • Figure 16: The National Health Services England: PCD Management
  • Figure 17: The National Health Services England: PCD Management
  • Figure 18: Unmet Needs of Primary Ciliary Dyskinesia
  • Figure 19: Total Prevalent Patient Population of PCD in the 7MM (2017-2028)
  • Figure 20: Total Prevalent Population of PCD in the US (2017-2028)
  • Figure 21: Diagnosed Cases of PCD in the US (2017-2028)
  • Figure 22: Clinical Manifestations of PCD in the US (2017-2028)

Figure 23 Situs Anomalies associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Figure 24 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in the US (2017-2028)

Figure 25 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in the US (2017-2028)

  • Figure 26: Other Manifestations associated with Primary Ciliary Dyskinesia in the US (2017-2028)
  • Figure 27: Total Prevalent Population of PCD in Germany (2017-2028)
  • Figure 28: Diagnosed Cases of PCD in Germany (2017-2028)
  • Figure 29: Clinical Manifestations of PCD in Germany (2017-2028)

Figure 30 Situs Anomalies associated with Primary Ciliary Dyskinesia in Germany (2017-2028)

Figure 31 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Germany (2017-2028)

Figure 32 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Germany (2017-2028)

  • Figure 33: Other Manifestations associated with Primary Ciliary Dyskinesia in Germany (2017-2028)
  • Figure 34: Total Prevalent Population of PCD in France (2017-2028)
  • Figure 35: Diagnosed Cases of PCD in France (2017-2028)
  • Figure 36: Clinical Manifestations of PCD in France (2017-2028)

Figure 37 Situs Anomalies associated with Primary Ciliary Dyskinesia in France (2017-2028)

Figure 38 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in France (2017-2028)

Figure 39 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in France (2017-2028)

  • Figure 40: Other Manifestations associated with Primary Ciliary Dyskinesia in France (2017-2028)
  • Figure 41: Total Prevalent Population of PCD in Italy (2017-2028)
  • Figure 42: Diagnosed Cases of PCD in Italy (2017-2028)
  • Figure 43: Clinical Manifestations of PCD in Italy (2017-2028)

Figure 44 Situs Anomalies associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Figure 45 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

Figure 46 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Italy (2017-2028)

  • Figure 47: Other Manifestations associated with Primary Ciliary Dyskinesia in Italy (2017-2028)
  • Figure 48: Total Prevalent Population of PCD in Spain (2017-2028)
  • Figure 49: Diagnosed Cases of PCD in Spain (2017-2028)
  • Figure 50: Clinical Manifestations of PCD in Spain (2017-2028)

Figure 51 Situs Anomalies associated with Primary Ciliary Dyskinesia in Spain (2017-2028)

Figure 52 Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Spain (2017-2028)

Figure 53 Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Spain (2017-2028)

  • Figure 54: Other Manifestations associated with Primary Ciliary Dyskinesia in Spain (2017-2028)
  • Figure 55: Total Prevalent Population of PCD in United Kingdom (2017-2028)
  • Figure 56: Diagnosed Cases of PCD in United Kingdom (2017-2028)
  • Figure 57: Clinical Manifestations of PCD in United Kingdom (2017-2028)

Figure 58 Situs Anomalies associated with PCD in United Kingdom (2017-2028)

Figure 59 Lower Respiratory Tract Anomalies associated with PCD in United Kingdom (2017-2028)

Figure 60 Upper Respiratory Tract Anomalies associated with PCD in United Kingdom (2017-2028)

  • Figure 61: Other Manifestations associated with PCD in United Kingdom (2017-2028)
  • Figure 62: Total Prevalent Population of PCD in Japan (2017-2028)
  • Figure 63: Diagnosed Cases of PCD in Japan (2017-2028)
  • Figure 64: Clinical Manifestations of PCD in Japan (2017-2028)
  • Figure 65: Situs Anomalies associated with Primary Ciliary Dyskinesia in Japan (2017-2028)
  • Figure 66: Lower Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Japan (2017-2028)
  • Figure 67: Upper Respiratory Tract Anomalies associated with Primary Ciliary Dyskinesia in Japan (2017-2028)
  • Figure 68: Other Manifestations associated with Primary Ciliary Dyskinesia in Japan (2017-2028)
  • Figure 69: Diagram of BEAT-PCD Workgroups (WG), overall aims and training opportunities
  • Figure 70: Susana Lopes from the Nova Medical School, Universidade Nova de Lisboa, Portugal presented on in vivo models of PCD
  • Figure 71: Mary Carroll from University Hospital Southampton, UK presented on the microbiome-pointers from CF
  • Figure 72: Cecilia Lo from the School of Medicine, University of Pittsburgh, USA presented on pulmonary morbidity in congenital heart disease and the shared genetic aetiology of PCD and heterotaxy
  • Figure 73: Claudia Kuehni from the Institute of Social and Preventive Medicine, University of Bern, Switzerland highlighted open questions, gaps and controversies in PCD epidemiology
  • Figure 74: Kim G. Nielsen from the Danish PCD Centre and Paediatric Pulmonary Service, Copenhagen University Hospital, Denmark presented on Pseudomonas infection - a growing problem in PCD
  • Figure 75: Hannah Mitchison from University College London, UK presented on PCD genetics as diagnostic test
  • Figure 76: Laura Behan from University of Southamton, UK and University College Cork, Ireland presented on Health related quality of life measures for PCD: QOL-PCD
  • Figure 77: Philipp Latzin from the University of Bern and the University of Basel, Switzerland presented on multiple-breath washout
  • Figure 78: Oliver Bieri from the University of Basel, Switzerland presented on lung MRI: overview and application in PCD
  • Figure 79: Egbert Biesheuvel from the FP7 ASTERIX project presented on methodological approaches to overcome the difficulties of conducting research in rare diseases
  • Figure 80: 7 Major Market Size of PCD in USD Million ( 2017-2028)
  • Figure 81: 7 Major Market Size of Primary Ciliary Dyskinesia by Therapies in USD Million (2017-2028)
  • Figure 82: The United States Market Size of PCD in USD Million ( 2017-2028)
  • Figure 83: The US Market Size of PCD by Therapies in USD Million (2017-2028)
  • Figure 84: Market Size of PCD in Germany, USD Million (2017-2028)
  • Figure 85: Germany Market Size of PCD by Therapies in USD Million (2017-2028)
  • Figure 86: Market Size of PCD in France USD Million ( 2017-2028)
  • Figure 87: France Market Size of PCD by Therapies in USD Million ( 2017-2028)
  • Figure 88: Market Size of PCD in Italy, USD Million ( 2017-2028)
  • Figure 89: Italy Market Size of PCD by Therapies in USD Million (2017-2028)
  • Figure 90: Market Size of PCD in Spain, USD Million (2017-2028)
  • Figure 91: Spain Market Size of PCD by Therapies in USD Million (2017-2028)
  • Figure 92: Market Size of PCD in the United Kingdom, USD Million (2017-2028)
  • Figure 93: The UK Market Size of PCD by Therapies in USD Million (2017-2028)
  • Figure 94: Market Size of PCD in Japan, USD Million (2017-2028)
  • Figure 95: The UK Market Size of PCD by Therapies in USD Million (2017-2028)
  • Figure 96: Market Drivers
  • Figure 97: Market Barriers